162 related articles for article (PubMed ID: 30159130)
21. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
22. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
23. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
26. Rescue of cell cycle progression in BRAF
Toress-Collado AX; Nazarian R; Jazirehi AR
Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
[TBL] [Abstract][Full Text] [Related]
27. Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals.
Tabolacci C; Cordella M; Mariotti S; Rossi S; Senatore C; Lintas C; Levati L; D'Arcangelo D; Facchiano A; D'Atri S; Nisini R; Facchiano F
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33467521
[TBL] [Abstract][Full Text] [Related]
28. Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
Jang GH; Kim NY; Lee M
Mol Cell Biochem; 2015 Aug; 406(1-2):53-62. PubMed ID: 25912549
[TBL] [Abstract][Full Text] [Related]
29. BRAFE600-associated senescence-like cell cycle arrest of human naevi.
Michaloglou C; Vredeveld LC; Soengas MS; Denoyelle C; Kuilman T; van der Horst CM; Majoor DM; Shay JW; Mooi WJ; Peeper DS
Nature; 2005 Aug; 436(7051):720-4. PubMed ID: 16079850
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
31. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
32. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
33. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
34. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
[TBL] [Abstract][Full Text] [Related]
35. Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas.
Figarola JL; Singhal J; Singhal S; Kusari J; Riggs A
Oncotarget; 2018 Dec; 9(97):36945-36965. PubMed ID: 30651927
[TBL] [Abstract][Full Text] [Related]
36. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.
Monsma DJ; Cherba DM; Eugster EE; Dylewski DL; Davidson PT; Peterson CA; Borgman AS; Winn ME; Dykema KJ; Webb CP; MacKeigan JP; Duesbery NS; Nickoloff BJ; Monks NR
Am J Cancer Res; 2015; 5(4):1507-18. PubMed ID: 26101714
[TBL] [Abstract][Full Text] [Related]
37. RSK2 promotes melanoma cell proliferation and vemurafenib resistance
Wu HZ; Li LY; Jiang SL; Li YZ; Shi XM; Sun XY; Li Z; Cheng Y
Front Pharmacol; 2022; 13():950571. PubMed ID: 36210843
[TBL] [Abstract][Full Text] [Related]
38. CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant Melanoma.
Torres GM; Jarnagin HC; Park C; Yang H; Kosarek NN; Bhandari R; Wang CY; Kolling FW; Whitfield ML; Turk MJ; Liby KT; Pioli PA
bioRxiv; 2023 Aug; ():. PubMed ID: 37577680
[TBL] [Abstract][Full Text] [Related]
39. Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells.
Su Y; Yu Y; He D; Zhang J; Wang Z; Sun P; Chen Z
Int J Clin Exp Pathol; 2018; 11(5):2550-2560. PubMed ID: 31938368
[TBL] [Abstract][Full Text] [Related]
40. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
